Skip to main content
PMC home page
American Journal of Human Genetics logoLink to American Journal of Human Genetics
. 1998 Oct;63(4):1160–1174. doi: 10.1086/302042

Prenatal screening for cystic fibrosis carriers: an economic evaluation.

P T Rowley 1, S Loader 1, R M Kaplan 1
PMCID: PMC1377475  PMID: 9758600

Abstract

The cloning of the CFTR gene has made it technically possible to avert the unwanted birth of a child with cystic fibrosis (CF). Several large trials offering prenatal CF carrier screening suggest that such screening is practical and that identified carriers generally use the information obtained. Therefore, a critical question is whether the cost of such screening is justified. Decision analysis was performed that used information about choices that pregnant women were observed to make at each stage in the Rochester prenatal carrier-screening trial. The cost of screening per CF birth voluntarily averted was estimated to be $1,320,000-$1,400,000. However, the lifetime medical cost of the care of a CF child in today's dollars was estimated to be slightly>$1,000,000. Therefore, despite both the high cost of carrier testing and the relative infrequency of CF conceptions in the general population, the averted medical-care cost resulting from choices freely made are estimated to offset approximately 74%-78% of the costs of a screening program. At present, if it is assumed that a pregnancy terminated because of CF is replaced, the marginal cost for prenatal CF carrier screening is estimated to be $8,290 per quality-adjusted life-year. This value compares favorably with that of many accepted medical services. The cost of prenatal CF carrier screening could fall to equal the averted costs of CF patient care if the cost of carrier testing were to fall to $100.

Full Text

The Full Text of this article is available as a PDF (367.1 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Asch D. A., Hershey J. C., Pauly M. V., Patton J. P., Jedrziewski M. K., Mennuti M. T. Genetic screening for reproductive planning: methodological and conceptual issues in policy analysis. Am J Public Health. 1996 May;86(5):684–690. doi: 10.2105/ajph.86.5.684. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Asch D. A., Patton J. P., Hershey J. C., Mennuti M. T. Reporting the results of cystic fibrosis carrier screening. Am J Obstet Gynecol. 1993 Jan;168(1 Pt 1):1–6. doi: 10.1016/s0002-9378(12)90875-3. [DOI] [PubMed] [Google Scholar]
  3. Botkin J. R. Prenatal screening: professional standards and the limits of parental choice. Obstet Gynecol. 1990 May;75(5):875–880. [PubMed] [Google Scholar]
  4. Brock D. J. Prenatal screening for cystic fibrosis: 5 years' experience reviewed. Lancet. 1996 Jan 20;347(8995):148–150. doi: 10.1016/s0140-6736(96)90340-2. [DOI] [PubMed] [Google Scholar]
  5. Chamberlain J. Human benefits and costs of a national screening programme for neural-tube defects. Lancet. 1978 Dec 16;2(8103):1293–1296. doi: 10.1016/s0140-6736(78)92053-6. [DOI] [PubMed] [Google Scholar]
  6. Chee M., Yang R., Hubbell E., Berno A., Huang X. C., Stern D., Winkler J., Lockhart D. J., Morris M. S., Fodor S. P. Accessing genetic information with high-density DNA arrays. Science. 1996 Oct 25;274(5287):610–614. doi: 10.1126/science.274.5287.610. [DOI] [PubMed] [Google Scholar]
  7. Cuckle H. S., Richardson G. A., Sheldon T. A., Quirke P. Cost effectiveness of antenatal screening for cystic fibrosis. BMJ. 1995 Dec 2;311(7018):1460–1464. doi: 10.1136/bmj.311.7018.1460. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Donaldson C., Shackley P., Abdalla M. Using willingness to pay to value close substitutes: carrier screening for cystic fibrosis revisited. Health Econ. 1997 Mar-Apr;6(2):145–159. doi: 10.1002/(sici)1099-1050(199703)6:2<145::aid-hec253>3.0.co;2-n. [DOI] [PubMed] [Google Scholar]
  9. Drummond M. F., Davies L. Economic analysis alongside clinical trials. Revisiting the methodological issues. Int J Technol Assess Health Care. 1991;7(4):561–573. doi: 10.1017/s0266462300007121. [DOI] [PubMed] [Google Scholar]
  10. Eddy D. M. Screening for breast cancer. Ann Intern Med. 1989 Sep 1;111(5):389–399. doi: 10.7326/0003-4819-111-5-389. [DOI] [PubMed] [Google Scholar]
  11. Epstein K. A., Schneiderman L. J., Bush J. W., Zettner A. The "abnormal" screening serum thyroxine (T4): analysis of physician response, outcome, cost and health effectiveness. J Chronic Dis. 1981;34(5):175–190. doi: 10.1016/0021-9681(81)90063-1. [DOI] [PubMed] [Google Scholar]
  12. Evers-Kiebooms G., Denayer L., Van den Berghe H. A child with cystic fibrosis: II. Subsequent family planning decisions, reproduction and use of prenatal diagnosis. Clin Genet. 1990 Mar;37(3):207–215. doi: 10.1111/j.1399-0004.1990.tb03504.x. [DOI] [PubMed] [Google Scholar]
  13. Ganiats T. G. Justifying prenatal screening and genetic amniocentesis programs by cost-effectiveness analyses: a re-evaluation. Med Decis Making. 1996 Jan-Mar;16(1):45–50. doi: 10.1177/0272989X9601600112. [DOI] [PubMed] [Google Scholar]
  14. Garber A. M., Fenerty J. P. Costs and benefits of prenatal screening for cystic fibrosis. Med Care. 1991 May;29(5):473–489. doi: 10.1097/00005650-199105000-00007. [DOI] [PubMed] [Google Scholar]
  15. Gill M., Murday V., Slack J. An economic appraisal of screening for Down's syndrome in pregnancy using maternal age and serum alpha fetoprotein concentration. Soc Sci Med. 1987;24(9):725–731. doi: 10.1016/0277-9536(87)90109-2. [DOI] [PubMed] [Google Scholar]
  16. Ginsberg G., Blau H., Kerem E., Springer C., Kerem B. S., Akstein E., Greenberg A., Kolumbos A., Abeliovich D., Gazit E. Cost-benefit analysis of a national screening programme for cystic fibrosis in an Israeli population. Health Econ. 1994 Jan-Feb;3(1):5–23. doi: 10.1002/hec.4730030104. [DOI] [PubMed] [Google Scholar]
  17. Hagard S., Carter F. A. Preventing the birth of infants with Down's syndrome: a cost-benefit analysis. Br Med J. 1976 Mar 27;1(6012):753–756. doi: 10.1136/bmj.1.6012.753. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Henderson J. B. Measuring the benefits of screening for open neural tube defects. J Epidemiol Community Health. 1982 Sep;36(3):214–219. doi: 10.1136/jech.36.3.214. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Levenkron J. C., Loader S., Rowley P. T. Carrier screening for cystic fibrosis: test acceptance and one year follow-up. Am J Med Genet. 1997 Dec 31;73(4):378–386. doi: 10.1002/(sici)1096-8628(19971231)73:4<378::aid-ajmg2>3.0.co;2-k. [DOI] [PubMed] [Google Scholar]
  20. Lieu T. A., Watson S. E., Washington A. E. The cost-effectiveness of prenatal carrier screening for cystic fibrosis. Obstet Gynecol. 1994 Dec;84(6):903–912. [PubMed] [Google Scholar]
  21. Loader S., Caldwell P., Kozyra A., Levenkron J. C., Boehm C. D., Kazazian H. H., Jr, Rowley P. T. Cystic fibrosis carrier population screening in the primary care setting. Am J Hum Genet. 1996 Jul;59(1):234–247. [PMC free article] [PubMed] [Google Scholar]
  22. Mennie M. E., Gilfillan A., Compton M., Curtis L., Liston W. A., Pullen I., Whyte D. A., Brock D. J. Prenatal screening for cystic fibrosis. Lancet. 1992 Jul 25;340(8813):214–216. doi: 10.1016/0140-6736(92)90476-j. [DOI] [PubMed] [Google Scholar]
  23. Miedzybrodzka Z., Semper J., Shackley P., Abdalla M., Donaldson C. Stepwise or couple antenatal carrier screening for cystic fibrosis?: women's preferences and willingness to pay. J Med Genet. 1995 Apr;32(4):282–283. doi: 10.1136/jmg.32.4.282. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Modell B., Kuliev A. M. Services for thalassaemia as a model for cost-benefit analysis of genetics services. J Inherit Metab Dis. 1991;14(4):640–651. doi: 10.1007/BF01797934. [DOI] [PubMed] [Google Scholar]
  25. Morris D. T. Cost containment and reproductive autonomy: prenatal genetic screening and the American Health Security Act of 1993. Am J Law Med. 1994;20(3):295–316. [PubMed] [Google Scholar]
  26. Nelson W. B., Swint J. M., Caskey C. T. A comment on the benefits and costs of genetic screening. Am J Hum Genet. 1978 Nov;30(6):663–665. [PMC free article] [PubMed] [Google Scholar]
  27. Old J. M., Fitches A., Heath C., Thein S. L., Weatherall D. J., Warren R., McKenzie C., Rodeck C. H., Modell B., Petrou M. First-trimester fetal diagnosis for haemoglobinopathies: report on 200 cases. Lancet. 1986 Oct 4;2(8510):763–767. doi: 10.1016/s0140-6736(86)90296-5. [DOI] [PubMed] [Google Scholar]
  28. Ostrowsky J. T., Lippman A., Scriver C. R. Cost-benefit analysis of a thalassemia disease prevention program. Am J Public Health. 1985 Jul;75(7):732–736. doi: 10.2105/ajph.75.7.732. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Riordan J. R., Rommens J. M., Kerem B., Alon N., Rozmahel R., Grzelczak Z., Zielenski J., Lok S., Plavsic N., Chou J. L. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science. 1989 Sep 8;245(4922):1066–1073. doi: 10.1126/science.2475911. [DOI] [PubMed] [Google Scholar]
  30. Rommens J. M., Iannuzzi M. C., Kerem B., Drumm M. L., Melmer G., Dean M., Rozmahel R., Cole J. L., Kennedy D., Hidaka N. Identification of the cystic fibrosis gene: chromosome walking and jumping. Science. 1989 Sep 8;245(4922):1059–1065. doi: 10.1126/science.2772657. [DOI] [PubMed] [Google Scholar]
  31. Rowley P. T., Loader S., Levenkron J. C. Cystic fibrosis carrier population screening: a review. Genet Test. 1997;1(1):53–59. doi: 10.1089/gte.1997.1.53. [DOI] [PubMed] [Google Scholar]
  32. Rowley P. T., Loader S., Levenkron J. C., Phelps C. E. Cystic fibrosis carrier screening: knowledge and attitudes of prenatal care providers. Am J Prev Med. 1993 Sep-Oct;9(5):261–266. [PubMed] [Google Scholar]
  33. Sadovnick A. D., Baird P. A. A cost-benefit analysis of prenatal detection of Down syndrome and neural tube defects in older mothers. Am J Med Genet. 1981;10(4):367–378. doi: 10.1002/ajmg.1320100409. [DOI] [PubMed] [Google Scholar]
  34. Schulman K. A., Linas B. P. Pharmacoeconomics: state of the art in 1997. Annu Rev Public Health. 1997;18:529–548. doi: 10.1146/annurev.publhealth.18.1.529. [DOI] [PubMed] [Google Scholar]
  35. Schwartz M., Brandt N. J., Skovby F. Screening for carriers of cystic fibrosis among pregnant women: a pilot study. Eur J Hum Genet. 1993;1(3):239–244. doi: 10.1159/000472417. [DOI] [PubMed] [Google Scholar]
  36. Torrance G. W., Zipursky A. Cost-effectiveness of antepartum prevention of Rh immunization. Clin Perinatol. 1984 Jun;11(2):267–281. [PubMed] [Google Scholar]
  37. Watson E. K., Mayall E., Chapple J., Dalziel M., Harrington K., Williams C., Williamson R. Screening for carriers of cystic fibrosis through primary health care services. BMJ. 1991 Aug 31;303(6801):504–507. doi: 10.1136/bmj.303.6801.504. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Weinstein M. C. Estrogen use in postmenopausal women--costs, risks, and benefits. N Engl J Med. 1980 Aug 7;303(6):308–316. doi: 10.1056/NEJM198008073030604. [DOI] [PubMed] [Google Scholar]
  39. Weinstein M. C., Siegel J. E., Gold M. R., Kamlet M. S., Russell L. B. Recommendations of the Panel on Cost-effectiveness in Health and Medicine. JAMA. 1996 Oct 16;276(15):1253–1258. [PubMed] [Google Scholar]
  40. Weinstein M. C., Stason W. B. Foundations of cost-effectiveness analysis for health and medical practices. N Engl J Med. 1977 Mar 31;296(13):716–721. doi: 10.1056/NEJM197703312961304. [DOI] [PubMed] [Google Scholar]
  41. Wertz D. C., Janes S. R., Rosenfield J. M., Erbe R. W. Attitudes toward the prenatal diagnosis of cystic fibrosis: factors in decision making among affected families. Am J Hum Genet. 1992 May;50(5):1077–1085. [PMC free article] [PubMed] [Google Scholar]
  42. Wilfond B. S., Fost N. The introduction of cystic fibrosis carrier screening into clinical practice: policy considerations. Milbank Q. 1992;70(4):629–659. [PubMed] [Google Scholar]

Articles from American Journal of Human Genetics are provided here courtesy of American Society of Human Genetics

RESOURCES